A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Sponsor
Eli Lilly and Company
Study ID
NCT06982859
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Diabetes Mellitus
  • Insulin Sensitivity

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.

Key Dates

Start date
Jun 2, 2025
Status verified
Feb 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
95 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Retatrutide
    Retatrutide administered subcutaneously (SC).
  • Active Comparator: Semaglutide
    Semaglutide administered SC.
  • Placebo Comparator: Placebo
    Placebo administered SC.

Primary Outcome Measure

Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo [ Time Frame: Baseline, Week 28 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Related Studies